clinical trial · NCT04803058
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
Kidney TransplantationTCD601
brief summary
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
started
Dec 14, 2022
primary completion
Mar 1, 2027
completion
Mar 1, 2030
last updated
Feb 6, 2026
official title
A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol